Andy Plump

Stories

Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance

Leading regulatory push and broader immunology expansion strategy

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

Updated May 15

Notable Quotes

"The level of efficacy that we're seeing, combined with the safety profile (and) with the convenience of administration, is quite unique in this landscape." — Andy Plump, Reuters

from Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance · Updated May 15

"[Takeda] has aspirations to enable all drug discovery and drug development with AI." — Andy Plump, Reuters

from Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance · Updated May 15